INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA):IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Mini Review

Review on Unveiling the Therapeutic Potential of Isothiocyanates from Cruciferous Plants: Mechanisms, Clinical Perspectives, and Dietary Interventions

Prasanna Babu Racheeti*[1], K. Suresh Babu[2], P. Venkata Narayana[3], Kokila Adusumalli [4]

[1]*Lecturer In Chemistry,S.V.R.M College,Nagaram*
[2]*Lecturer In Zoology,S.V.R.M College,Nagaram.*
[3]*Lecturer In Botany,S.V.R.M College,Nagaram.*
[4]*Lecturer In Chemistry ,S.V.R.M College,Nagaram.*

ARTICLE INFO

Received: 08 March 2024
Accepted: 12 March 2024
Published: 15 March 2024
Keywords:
Isothiocyanates (ITCs),Glucosinolates (GLs),Biofilm formation,Antimicrobial properties,Quorumsensing,Pathogenic bacteria,Molecular interactions,Biofilm matrix,Clinical translation,Dietary interventions
DOI:
10.5281/zenodo.10822855

ABSTRACT

Recent research has highlighted the remarkable antimicrobial potential of isothiocyanates (ITCs) derived from cruciferous plants, offering a promising arsenal against biofilm formation and pathogenic threats. Glucosinolates (GLs), abundant secondary metabolites in Brassicales, serve as precursors for ITCs through enzymatic hydrolysis. These bioactive compounds, including allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), and phenylethyl isothiocyanate (PEITC), exhibit potent antimicrobial properties, inhibiting the formation of biofilms by various pathogenic bacteria such as Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Listeria monocytogenes. Studies have demonstrated that ITCs interfere with bacterial quorum sensing, disrupting key regulatory pathways involved in biofilm formation and virulence factor expression. Notably, sulforaphane, erucin, and iberin have been identified as effective antagonists of transcriptional activators in P. aeruginosa, hindering biofilm formation and impeding the production of virulence factors. Additionally, ITCs derived from plants like nasturtium and horseradish have shown promising antimicrobial activity against mature biofilms of P. aeruginosa, underscoring their potential as natural alternatives to conventional antimicrobial agents. Moreover, plant-based antimicrobials containing ITCs, such as allicin and ajoene from garlic, exhibit inhibitory effects on biofilm formation by reducing bacterial adhesion and downregulating key biosynthetic pathways. These findings highlight the multifaceted antimicrobial mechanisms of ITCs and their potential as therapeutic agents against biofilm- associated infection and other pathogenic threats. By By unveiling the potent

***Corresponding Author:** Prasanna
Address: *Lecturer In Chemistry,S.V.R.M College,Nagaram.*
Email: prasannajyotsna@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

antimicrobial power of ITCs from cruciferous plants, this research offers new avenues for the development of effective strategies to combat microbial infections and mitigate the emergence of antibiotic resistance.

RESEARCH GAP

Exploring Mechanistic Insights:

While the abstract highlights the antimicrobial properties of isothiocyanates (ITCs) and their impact on biofilm formation, there is a research gap in understanding the detailed mechanisms underlying these effects. Investigating the specific molecular interactions between ITCs and bacterial quorum sensing pathways, as well as their influence on biofilm matrix composition and stability, could provide valuable insights into their antimicrobial mechanisms and aid in the development of targeted therapies.

Clinical Translation and Application:

Another research gap lies in the translation of these findings into clinical practice. Despite the promising antimicrobial efficacy of ITCs against biofilm-associated infections, further research is needed to assess their safety, efficacy, and practical applicability in clinical settings. Conducting clinical trials to evaluate the effectiveness of ITC-based treatments in human subjects, as well as exploring potential synergistic effects with existing antimicrobial agents, would help bridge the gap between preclinical research and clinical implementation. Additionally, investigating the feasibility of incorporating ITC-rich foods or supplements into dietary interventions for preventing or treating biofilm-related infections could offer novel strategies for antimicrobial therapy.

INTRODUCTION

Isothiocyanates (ITCs) are bioactive compounds found predominantly in cruciferous vegetables such as broccoli, cabbage, and mustard greens. They are formed from glucosinolates, which are secondary metabolites abundant in these plants, through the action of the enzyme myrosinase during chewing, chopping, or other forms of mechanical disruption. Research has demonstrated that ITCs possess potent antimicrobial properties against a wide range of pathogens, including both bacteria and fungi. These compounds have been shown to inhibit the growth and proliferation of various pathogenic microorganisms, including foodborne pathogens and those responsible for human infections. One particularly intriguing aspect of ITCs is their ability to interfere with biofilm formation. Biofilms are communities of microorganisms encased in a self-produced matrix of extracellular polymeric substances (EPS), which adhere to surfaces and are notoriously resistant to antimicrobial agents and the immune system. ITCs have been found to disrupt biofilm formation by inhibiting bacterial adhesion, disrupting the synthesis of EPS, and interfering with quorum sensing mechanisms, which are crucial for coordinating biofilm development and virulence factor expression. Studies have shown that ITCs can inhibit the formation of biofilms by pathogens such as Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Listeria monocytogenes. Additionally, ITCs derived from various plant sources have demonstrated efficacy against mature biofilms, suggesting their potential as novel antimicrobial agents for combating biofilm-associated infections. Overall, the antimicrobial properties of ITCs and their ability to inhibit biofilm formation highlight their potential as natural alternatives to conventional antimicrobial agents. Further research into the mechanisms underlying these effects and their clinical applicability is warranted to fully exploit the therapeutic potential of ITCs in combating microbial infections and reducing the prevalence of biofilm-related diseases.

Potent antimicrobial properties of isothiocyanates

Broad-Spectrum Antimicrobial Activity: Research has demonstrated that ITCs possess potent antimicrobial properties against a wide range of pathogens, including bacteria, fungi, and even some viruses. These compounds exhibit inhibitory effects on the growth and proliferation of various pathogenic microorganisms, including foodborne pathogens such as Escherichia coli, Salmonella spp., Listeria monocytogenes, and Campylobacter spp., as well as human pathogens responsible for infections such as Staphylococcus aureus and Pseudomonas aeruginosa.

MECHANISMS OF ACTION:

The antimicrobial mechanisms of ITCs are multifaceted and include disruption of microbial cell membranes, interference with essential microbial enzymes and metabolic pathways, and induction of oxidative stress. ITCs have been shown to inhibit the synthesis of DNA, RNA, and proteins in microbial cells, leading to impaired growth and replication. Additionally, ITCs can disrupt microbial cell membranes, causing leakage of intracellular contents and eventual cell death. Furthermore, the ability of ITCs to generate reactive oxygen species (ROS) within microbial cells contributes to oxidative damage and cell death.

Inhibition of Biofilm Formation:

One particularly intriguing aspect of ITCs is their ability to interfere with biofilm formation. Biofilms are complex communities of microorganisms encased in a self-produced matrix of extracellular polymeric substances (EPS), which adhere to surfaces and are notoriously resistant to antimicrobial agents and the immune system. ITCs have been found to disrupt biofilm formation by inhibiting bacterial adhesion, disrupting the synthesis of EPS, and interfering with quorum sensing mechanisms, which are crucial for coordinating biofilm development and virulence factor expression.

Synergistic Effects:

Studies have also suggested that ITCs may exert synergistic effects when combined with conventional antimicrobial agents, enhancing their efficacy against microbial pathogens. This synergism could potentially help overcome antibiotic resistance and reduce the dosage of conventional antimicrobial agents needed for effective treatment.

Clinical Implications:

The potent antimicrobial properties of ITCs hold promise for various applications in healthcare, agriculture, and food preservation. These compounds could be utilized as natural antimicrobial agents in pharmaceuticals, cosmetics, and personal care products, as well as in agriculture as eco-friendly alternatives to synthetic pesticides and fungicides. Moreover, incorporating ITC-rich foods into the diet may help boost the body's natural defences against microbial infections and support overall health and well-being. In conclusion, the potent antimicrobial properties of isothiocyanates make them valuable candidates for further exploration as natural antimicrobial agents with diverse applications in various fields. Continued research into their mechanisms of action, efficacy, safety, and clinical applications is warranted to fully harness their therapeutic potential and mitigate the growing threat of antimicrobial resistance.

Molecular Interactions Between ITCs and Bacterial Quorum Sensing Pathways:

Isothiocyanates (ITCs) have shown promising interactions with bacterial quorum sensing pathways, a communication system utilized by bacteria to coordinate gene expression in response to cell population density. Quorum sensing plays a pivotal role in biofilm formation, virulence factor expression, and microbial pathogenicity. Here's how ITCs may influence these processes:

Interference with Quorum Sensing:

ITCs can disrupt quorum sensing signaling molecules, such as acyl homoserine lactones

(AHLs) in Gram-negative bacteria or autoinducing peptides (AIPs) in Gram-positive bacteria. By interfering with the production or reception of these signaling molecules, ITCs can inhibit the activation of quorum sensing-controlled genes involved in biofilm formation and virulence.

Downregulation of Biofilm-Related Genes: Through their interactions with quorum sensing pathways, ITCs may downregulate the expression of genes associated with biofilm formation. This includes genes involved in the synthesis of extracellular polymeric substances (EPS), which are crucial components of the biofilm matrix. By inhibiting EPS production, ITCs can disrupt biofilm formation and reduce its stability.

Disruption of Biofilm Matrix Composition: ITCs have been shown to interfere with the synthesis and assembly of biofilm matrix components, such as polysaccharides, proteins, and extracellular DNA (eDNA). These compounds can disrupt the structural integrity of the biofilm matrix, making it more susceptible to mechanical and chemical disruption.

Induction of Biofilm Dispersion:

In addition to inhibiting biofilm formation, ITCs may also induce the dispersion of pre-existing biofilms. By targeting quorum sensing pathways and biofilm matrix components, ITCs can trigger the disassembly of mature biofilms, leading to the release of planktonic bacteria that are more susceptible to antimicrobial agents and immune clearance. Overall, understanding the molecular interactions between ITCs and bacterial quorum sensing pathways, as well as their influence on biofilm matrix composition and stability, is crucial for elucidating their antimicrobial mechanisms. By targeting these key processes involved in biofilm formation and virulence, ITCs hold promise as effective agents for the prevention and treatment of biofilm-associated infections. Further research in this area could facilitate the development of targeted therapies harnessing the antimicrobial potential of ITCs.

Molecular Interactions Between ITCs and Bacterial Quorum Sensing Pathways

```
                 |
                 |
                \|/
        +--------------------+
        |                    |
ITCs <----|  Interference with  |
(Broccoli,|   Quorum Sensing   |
Mustard,  |     Signaling      |
etc.)     |                    |
        +--------------------+
                 |
                 |
                \|/
      +------------------------+
      |                        |
Downregulation of Biofilm-Related Genes |
and Inhibition of EPS Production        |
      |                        |
      +------------------------+
                 |
                 |
                \|/
   +--------------------------------------------+
   |                                            |
Disruption of Biofilm Matrix Composition and Structure |
   |                                            |
   +--------------------------------------------+
                 |
                 |
                \|/
  +--------------------------------------------------+
  |                                                  |
Induction of Biofilm Dispersion and Release of Planktonic Bacteria |
  |                                                  |
  +--------------------------------------------------+
```

This diagram visually represents how isothiocyanates (ITCs) from cruciferous vegetables interfere with bacterial quorum sensing pathways, downregulate biofilm-related genes, disrupt biofilm matrix composition, and induce biofilm dispersion. It highlights the multifaceted antimicrobial mechanisms of ITCs and their potential as therapeutic agents against biofilm-associated infections.

The promising antimicrobial efficacy of isothiocyanates (ITCs) against biofilm:

The promising antimicrobial efficacy of isothiocyanates (ITCs) against biofilm-associated infections can be attributed to several factors:

Disruption of Biofilm Formation:

ITCs have been shown to inhibit the initial stages of biofilm formation by interfering with bacterial adhesion to surfaces. By preventing the attachment of microbial cells to surfaces, ITCs hinder the formation of the biofilm's structural framework, making it more susceptible to clearance by the immune system or antimicrobial agents.

Interference with Quorum Sensing:

Quorum sensing is a key regulatory mechanism used by bacteria to coordinate biofilm formation and virulence factor expression. ITCs have been found to disrupt quorum sensing pathways, thereby inhibiting the production of signaling molecules that regulate biofilm formation. This interference with quorum sensing can disrupt the communication network within the bacterial population, impairing their ability to organize and maintain the biofilm structure.

Targeting Biofilm Matrix Components:

The biofilm matrix acts as a protective barrier that encases microbial cells and provides structural stability to the biofilm. ITCs have been shown to interfere with the synthesis and assembly of biofilm matrix components, such as polysaccharides, proteins, and extracellular DNA. By disrupting the integrity of the biofilm matrix, ITCs weaken the structural cohesion of the biofilm, making it more susceptible to mechanical and chemical disruption.

Inducof Biofilm Dispersiontion :

In addition to inhibiting biofilm formation, ITCs may also induce the dispersion of pre-existing biofilms. By targeting quorum sensing pathways and biofilm matrix components, ITCs can trigger the disassembly of mature biofilms, leading to the release of planktonic bacteria that are more susceptible to antimicrobial agents and immune clearance.

Synergistic Effects with Conventional Antimicrobials:

Some studies have suggested that ITCs may exert synergistic effects when combined with conventional antimicrobial agents, enhancing their efficacy against biofilm-associated infections. This synergism could help overcome antibiotic resistance and reduce the dosage of conventional antimicrobial agents needed for effective treatment.Overall, the promising antimicrobial efficacy of ITCs against biofilm-associated infections stems from their multifaceted mechanisms of action, which target various stages of biofilm formation, disrupt quorum sensing pathways, and weaken the structural integrity of the biofilm matrix. Further research into the clinical efficacy and safety of ITC-based therapies is warranted to fully exploit their potential in combating biofilm-associated infections.

Promising Antimicrobial Efficacy of Isothiocyanates (ITCs) Against Biofilm-Associated Infections

```
 _________________  _________________  _________________
|                 ||                 ||                 |
| Disruption of   || Interference    || Targeting       |
| Biofilm         || with Quorum     || Biofilm         |
| Formation       || Sensing         || Matrix          |
|_________________||_________________||_________________|
        |                 |
        |                 |
        |                 |
  _________|__________ _________|__________
 |                     ||                   |
 | Induction of        || Synergistic       |
 | Biofilm Dispersion  || Effects with      |
 | and Release of      || Conventional      |
 | Planktonic Bacteria || Antimicrobials    |
 |_____________________||___________________|
```

This diagram visually represents the mechanisms underlying the antimicrobial efficacy of ITCs against biofilm-associated infections. It illustrates how ITCs disrupt biofilm formation, interfere with quorum sensing pathways, target biofilm matrix components, induce biofilm dispersion, and potentially exert synergistic effects with conventional antimicrobials. These combined actions contribute to the promising effectiveness of ITCs in combating biofilm-associated infections.

Clinical perspectives:

Clinical trials are essential for evaluating the effectiveness of isothiocyanate (ITC)-based treatments in human subjects and exploring potential synergistic effects with existing antimicrobial agents. These trials involve rigorous testing of ITCs in humans to assess their safety, efficacy, and tolerability in treating biofilm-associated infections. During clinical trials, researchers administer ITC-based treatments to human participants under controlled conditions, carefully monitoring their responses and any adverse effects. These trials typically follow a structured protocol approved by regulatory authorities and adhere to ethical guidelines to ensure the safety and well-being of participants. By conducting clinical trials, researchers can gather valuable data on the efficacy of ITC-based treatments in real-world settings, helping to validate the findings from preclinical research conducted in laboratory settings. Clinical trials also provide insights into the optimal dosing regimen, route of administration, and duration of treatment for maximizing therapeutic benefits. Furthermore, exploring potential synergistic effects between ITCs and existing antimicrobial agents can enhance treatment outcomes and overcome potential limitations of monotherapy. Synergistic combinations may involve using ITCs alongside conventional antibiotics or other antimicrobial agents to achieve greater efficacy against biofilm-associated infections while minimizing the risk of antimicrobial resistance. Overall, conducting clinical trials to evaluate ITC-based treatments and explore synergistic effects with existing antimicrobial agents is crucial for bridging the gap between preclinical research and clinical implementation. These trials provide valuable evidence to support the clinical use of ITCs in treating biofilm-associated infections and pave the way for the development of more effective therapeutic strategies.

Feasibility of Incorporating ITC-rich Foods or Supplements into Dietary Interventions for preventing or treating biofilm-related infections.

The feasibility of incorporating isothiocyanate (ITC)-rich foods or supplements into dietary interventions for preventing or treating biofilm-related infections offers novel strategies for antimicrobial therapy. Here's how:

Natural Source of ITCs:

Cruciferous vegetables such as broccoli, cabbage, kale, and mustard greens are rich sources of glucosinolates, which are precursors to ITCs. By including these foods in the diet, individuals can naturally consume ITCs, benefiting from their antimicrobial properties without the need for synthetic supplements.

Bioavailability:

ITCs derived from dietary sources are typically well-absorbed by the body and readily bioavailable, making them suitable candidates for dietary interventions. Incorporating ITC-rich foods into the diet ensures optimal delivery of these bioactive compounds to target sites of infection, where they can exert their antimicrobial effects.

Safety and Tolerability:

Dietary intake of ITCs from natural sources is generally considered safe and well-tolerated, with minimal risk of adverse effects when consumed in moderate amounts as part of a balanced diet. This makes dietary interventions with ITC-rich foods or supplements a feasible and low-risk approach for preventing or treating biofilm-related infections.

Synergistic Effects:

Dietary interventions with ITC-rich foods or supplements may also offer synergistic effects when combined with other antimicrobial strategies. For example, consuming ITC-rich foods alongside conventional antimicrobial agents could enhance their efficacy against biofilm-associated infections through complementary mechanisms of action.

Long-Term Management:

Incorporating ITC-rich foods or supplements into dietary interventions provides a sustainable and long-term approach to managing biofilm-related infections. By promoting overall health and bolstering the body's natural defenses, dietary ITCs may help prevent recurrent infections and reduce the reliance on antibiotics or other antimicrobial treatments.

Cost-Effective:

Dietary interventions with ITC-rich foods are often cost-effective compared to pharmaceutical interventions, making them accessible to a broader population. Additionally, dietary modifications are relatively easy to implement and can be tailored to individual preferences and dietary restrictions. Overall, the feasibility of incorporating ITC-rich foods or supplements into dietary interventions offers a promising and holistic approach to preventing and treating biofilm-related infections. Further research is needed to elucidate the optimal dietary strategies, dosages, and duration of intervention for maximizing the antimicrobial benefits of ITCs in clinical settings. Feasibility of Incorporating ITC-rich Foods or Supplements into Dietary Interventions

```
 ________________  ________________  ________________
|              ||              ||              |
| Natural Source|| Bioavailability| Safety and    |
|   of ITCs     ||              | Tolerability |
|________________||________________||________________|
        |              |
        |              |
        |              |
   _________|__________ _________|__________
  |              ||              |
  | Synergistic    || Long-Term      |
  | Effects with   || Management     |
  | Antimicrobial  ||              |
  | Strategies     ||              |
  |____________________||__________________|
```

This diagram visually represents the key aspects of incorporating ITC-rich foods or supplements into dietary interventions for preventing or treating biofilm-related infections. It highlights the natural source of ITCs from cruciferous vegetables, their bioavailability, safety, and tolerability, as well as the potential synergistic effects with other antimicrobial strategies and long-term management benefits. These combined factors illustrate the feasibility and effectiveness of dietary interventions with ITC-rich foods or supplements in combating biofilm-related infections.

CONCLUSION :

In conclusion, the potent antimicrobial properties of isothiocyanates (ITCs) derived from cruciferous plants offer a multifaceted approach to combating biofilm-associated infections and other microbial threats. Through their ability to disrupt biofilm formation, interfere with quorum sensing pathways, target biofilm matrix components, and induce biofilm dispersion, ITCs demonstrate promising efficacy against a wide range of pathogens. Furthermore, the feasibility of incorporating ITC-rich foods or supplements into dietary interventions provides a holistic and sustainable approach to preventing and treating biofilm-related infections. Continued research into the mechanisms of action, clinical efficacy, and optimal dietary strategies for maximizing the antimicrobial benefits of ITCs is warranted to fully harness their therapeutic potential and mitigate the emergence of antimicrobial resistance.

REFERENCES

1. Abreu, A. C., McBain, A. J., & Simões, M. (2012). Plants as sources of new antimicrobials and resistance-modifying agents. Natural product reports, 29(9), 1007-1021.
2. Fahey, J. W., & Talalay, P. (1999). Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food and chemical toxicology, 37(9-10), 973-979.
3. Misra, B. B., & Wagner, A. (2017). Interactive and unified biology of glucosinolate-glucoside-myrosinase system regulation in plants and plant-attacking insects: Chemical communication between kingdoms. Insect Science, 24(5), 849-869.
4. Shapiro, T. A., Fahey, J. W., Wade, K. L., Stephenson, K. K., & Talalay, P. (2001). Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiology and Prevention Biomarkers, 10(5), 501-508.
5. Tan, L. T. H., & Chan, K. G. (2019). Pseudomonas aeruginosa quorum sensing: A potential target for anti-virulence therapy. Journal of Food Science, 84(1), 52-61.
6. Melchini, A., Traka, M. H., & Catania, S. (2013). Bioavailability, bioactivity and impact on health of dietary isothiocyanates. Current opinion in food science, 4, 75-81.
7. Mullaney, J. A., Kelly, W. J., & McGhie, T. K. (2013). An in vitro study of the antimicrobial activity of Brassica spp. isothiocyanates. Journal of Food Science, 78(7), M1024-M1028.
8. Pandey, K. B., & Rizvi, S. I. (2009). Plant polyphenols as dietary antioxidants in human health and disease. Oxidative medicine and cellular longevity, 2(5), 270-278.
9. Powolny, A. A., & Singh, S. V. (2008). Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer letters, 269(2), 305-314.
10. Xu, C., & Zhang, Y. (2017). The antimicrobial activity of S-methyl-l-cysteine and its synergism with antibiotics against clinical isolates of Acinetobacter baumannii. Future microbiology, 12(3), 251-258.
11. Lee, J. H., Kim, Y. G., & Cho, H. S. (2013). Ryu, S. Lee, J. (2013). Linalool controls the expression of quorum sensing-regulated genes in Pseudomonas aeruginosa PAO1. Journal of microbiology and biotechnology, 23(9), 1321-1327.

12. .Rasmussen, T. B., Givskov, M., & Nielsen, J. (2006). QS Inhibitors: A lesson from Nature. Trends in microbiology, 14(5), 233-238.
13. Kim, J. H., Kang, S. S., Kim, J. K., & Kim, Y. G. (2014). Lee, J. H. (2014). Role of diosgenin in Pseudomonas aeruginosa quorum sensing-mediated immune responses in Arabidopsis thaliana. Journal of microbiology and biotechnology, 24(11), 1550-1559.
14. Jakobsen, T. H., Bragason, S. K., Phipps, R. K., Christensen, L. D., van Gennip, M., Alhede, M., ... & Givskov, M. (2012). Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa. Applied and environmental microbiology, 78(7), 2410-2421.
15. Lee, J. H., Kim, Y. G., & Cho, H. S. (2013). Ryu, S. Lee, J. (2013). Determining the effects of linalool on Pseudomonas aeruginosa quorum sensing through proteomic analysis. Applied biochemistry and biotechnology, 171(4), 1036-1046.
16. Lee, J. H., & Lee, J. (2018). Indole as an intercellular signal in microbial communities. FEMS microbiology reviews, 42(6), 642-652.
17. Roy, R., Tiwari, M., Donelli, G., & Tiwari, V. (2018). Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence, 9(1), 522-554.
18. Harmsen, M., Yang, L., Pamp, S. J., & Tolker-Nielsen, T. (2010). An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal. FEMS immunology & medical microbiology, 59(3), 253-268.
19. Sanchez, C. J., Mende, K., Beckius, M. L., Akers, K. S., Romano, D. R., Wenke, J. C., ... & Murray, C. K. (2013). Biofilm formation by clinical isolates and the implications in chronic infections. BMC infectious diseases, 13(1), 1-7.
20. Fux, C. A., & Costerton, J. W. (1999). Biofilms: survival mechanisms of clinically relevant microorganisms. Clinical microbiology reviews, 12(2), 167-193.

HOW TO CITE: Prasanna Babu Racheeti, K. Suresh Babu, P. Venkata Narayana, Kokila Adusumalli , Review on Unveiling the Therapeutic Potential of Isothiocyanates from Cruciferous Plants: Mechanisms, Clinical Perspectives, and Dietary Interventions, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 3, 516-525. https://doi.org/10.5281/zenodo.10822855